EAHP represents over 29,000 hospital pharmacists across 36 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professionals.
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic of Germany and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
At EAHP, we are committed to transparency in our governance, ethical standards, and funding practices. This section provides open access to our foundational documents, including the EAHP Statutes, Code of Conduct, and Funding Sources. By sharing these resources, we aim to uphold accountability and foster trust with our members, partners, and the public.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
Sponsor Channel
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
The EAHP EU Monitor is a regular round up of news relevant to hospital pharmacy in Europe.
You can subscribe to receive the EAHP EU Monitor by email HERE.
The 2019 Medicines Shortages Survey of the European Association of Hospital Pharmacists (EAHP) seeks to investigate the reasons and impact of medicines shortages on patients in European hospitals as well as possible solutions. Until 13th January 2020, hospital pharmacists, other healthcare professionals working in the hospital environment and patients that have experienced medicines shortages are invited to contribute to the survey.
EAHP has been active on the issue of medicines shortages for over ten years and has conducted several Medicines Shortages Surveys. Findings of the most recent investigation showed that medicines shortages in European hospitals increased between 2014 and 2018. EAHP is extremely concerned by this development, in particular since the quality and safety of patient care is significantly affected. Patients are at risk of suffering deterioration in their health status if they cannot receive their prescribed medicines in a timely manner. Simultaneously, the amount of time that different healthcare professionals are able to spend with patients is reduced by the increased necessity of investing more and more working hours into the management of medicines shortages.
The survey is available in several different languages. EAHP encourages hospital pharmacists, doctors, nurses, patients and all other healthcare professionals to share their views via one of the following surveys:
The European Medicines Agency (EMA) released an update on metformin diabetes medicines. In addition, the annex to the guidelines on excipients in the labelling and package leaflet of medicinal products for human use was made available as well as a timeline outlining the journey of a medicine assessed by EMA.
EMA update on metformin diabetes medicines
EMA is aware that trace amounts of an impurity, N-nitrosodimethylamine (NDMA), have been found in a small number of metformin diabetes medicines outside the EU. The levels of NDMA in the affected non-EU metformin medicines are very low and appear to be within or even below the range that people can be exposed to from other sources, including certain foods and water.
At this point, there are no data indicating that EU metformin medicines are affected. Authorities in the EU are in the process of working with companies to test EU medicines and will provide further updates as more information becomes available. Patients in the EU should continue taking their metformin medicines as normal. The risk from not having adequate diabetes treatment far outweighs possible effects of the low levels of NDMA seen in tests. Healthcare professionals should remind patients of the importance of keeping their diabetes under control. Metformin is widely used alone or in combination with other medicines to treat type 2 diabetes. It is usually the first-line treatment, and it works by reducing the production of glucose in the body and reducing its absorption from the gut.
Further information is available HERE
Annex to the guideline on excipients in the labelling and package leaflet of medicinal products for human use
A revised guideline on excipients labelling was published in spring 2018, following a targeted stakeholder consultation carried out by the European Commission. The corresponding annex which contains a list of all excipients known to have a recognised action or effect that need to be displayed on the label of any medicine authorised in the European Union was made available in November 2019.
Access the annex HERE
Timeline describing the journey of a medicines for human use
Earlier in December, an interactive timeline describing the journey of a medicine for human use authorised through EMA was published. The tool allows the user to navigate information about the different stages, starting from the initial research, more easily. It explains in particular how EMA supports medicine development by providing scientific advice, how it assesses a medicine’s benefits and risks to decide whether it should be granted marketing authorisation, and then continues monitoring its effects when it is used by patients.
Access the timeline HERE
The Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections (EU JAMRAI) has launched a design contest to find a symbol that can be associated with the fight against antimicrobial resistance (AMR). The contest is open to anyone that wishes to contribute to raising awareness about the problem of resistance against antibiotics.
Participants who like science, have a creative mind or want to make a change are encouraged to enter this contest. Entries will be accepted until the 31st of March 2020, and the winner will be announced next summer. Submissions to the contest will be judged by a multidisciplinary and multisectoral jury, including representatives from EU-JAMRAI and the European Centre for Disease Prevention and Control (ECDC), other members of its stakeholder forum, scientists, regulatory bodies and patient organisations.
Further information and the contest rules, can be accessed HERE
The latest original article published in the online first edition of the European Journal of Hospital Pharmacy (EJHP) shares the results of an assessment of the feasibility, acceptability and effectiveness of a novel pharmacy-led intervention for patients hospitalised with acute coronary syndrome. The findings demonstrate the importance of conducting feasibility and acceptability studies when developing adherence innovations in clinical care. Future studies should consider enhancing the training process to ameliorate fidelity issues.
Read the article HERE
EAHP is looking for hospital pharmacists that are interested in expanding their horizon by joining the Statement Implementation Learning Collaborative Centres (SILCC) programme. SILCC fellows are provided with the opportunity to visit hospitals (SILCC hosts) from other EAHP member countries to learn about pharmacy procedures linked to the European Statements of Hospital Pharmacy. Further information, including on the application procedure is available on EAHP’s Statement website.
EDQM – Public consultation for revised dosage form monographs and general chapters
The European Pharmacopoeia (Ph. Eur.) Commission is undertaking a review of five different texts. These include the general monograph for eye preparations (1163), the new general chapter “Particulate contamination: sub-visible particles in non-injectable liquid preparations (2.9.53)”, the text on uniformity and accuracy of delivered doses from multidose containers (2.9.27) and the ones on ear preparations (0652) as well as liquid preparations for cutaneous application (0927).
Deadline – 31st December 2019
Further information available HERE
